2008 Innovation Summit to Feature Speakers from BD (Becton, Dickinson and Company), Merck and Celgene
Madison, NJ (April 11, 2008) – What is innovation within an organization and how can businesses implement it to foster corporate growth? On April 30, 2008, join healthcare innovation leaders as they share their insights and thoughts.
The 2008 Innovation Summit is designed to help management learn how to implement innovation within their organizations and attendees will have the opportunity to hear how three innovation leaders from the healthcare industry have used innovation to foster corporate growth. The day will also include remarks by Angie McGuire, Deputy Director, Office of Economic Growth, State of New Jersey. The event is one of the innovation outreach programs of the Rothman Institute of Entrepreneurial Studies, Silberman College of Business at FDU.
Edward J. Ludwig serves as Chairman, President and Chief Executive Officer of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey.
Mr. Ludwig’s career with BD has spanned more than 30 years, beginning in 1979. His previous roles have included President, Becton Dickinson Diagnostic Systems; Vice President, Planning and Development; Senior Vice President and Chief Financial Officer. Named President in May 1999 and Chief Executive Officer in January 2000, Mr. Ludwig was elected Chairman in February 2002.
Prior to joining BD, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now Pricewaterhouse Coopers) and as a financial and strategic analyst at Kidde, Inc.
Mr. Ludwig is also active philanthropically, as he is a member of the Board of Trustees of the College of the Holy Cross and a member and past Chair of the Health Advisory Board for the Johns Hopkins Bloomberg School of Public Health. Mr. Ludwig was appointed to Aetna’s Board of Directors in July 2003 and chairs the Audit Committee. Mr. Ludwig graduated from The College of the Holy Cross with a B.A. in Economics and Accounting and received his M.B.A. in Finance from Columbia University. He is also a C.P.A.
Dr. Mervyn Turner serves as Senior Vice President, Worldwide Licensing & External Research, Merck & Co., Inc. He is responsible for the oversight of all of Merck’s licensing activities and for the management of academic relations. Dr. Turner’s career with Merck began in 1985, and through his multiple and diverse experiences in the Merck Research Laboratories, he has acquired a broad perspective on the issues surrounding drug discovery and development.
2004 through 2007 saw a sizeable increase in deal activity for Merck, with over 190 transactions completed. Dr. Turner sees all this activity as a logical product of a cultural shift within Merck towards a more outward-facing organization.
Dr. Turner is the author of over 80 articles in peer-reviewed journals. He has served on the Editorial Board of a number of journals, and since 1998 has been a member of Health Care Ventures Scientific Advisory Board.
Robert J. Hugin is President and Chief Operating Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease. He joined Celgene in 1999 and has been a Director of Celgene since December 2001.
Mr. Hugin also serves as a Director of The Medicines Company, Atlantic Health System, Inc. and of Family Promise, a national non-profit network assisting homeless families. Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. He received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period.
The speakers will be followed by a distinguished panel of biotech/pharma entrepreneurs and leaders that will share insights on implementing innovation at start-ups and smaller, growth companies. The panel includes Arthur Alfaro, Founder and CEO, ORTHOCON; Vivian Liu, Co-founder and CEO, NexMed; Elizabeth Posillico, President and CEO, Elusys Therapeutics, Inc.; and Glenn Sblendorio, EVP and CFO, The Medicines Company.
The 2008 Innovation Summit will be held at FDU’s College of Florham Campus, 285 Madison Avenue, Madison, NJ, and the cost is $145. The summit begins with breakfast promptly at 7 a.m. and concludes at noon with a networking session.
The Summit is sponsored by Schering-Plough Corporation, Johnson & Johnson, Innosight, Verasoni Worldwide, Amper, Politziner & Mattia, The Research and Development Council of New Jersey, Schenck, Price, Smith & King, NJN, NJBIZ, Moran Media Group, Bloomberg, the Council on Competitiveness, Fairleigh Dickinson University’s Rothman Institute of Entrepreneurial Studies and the FDU’s Silberman College of Business.
Pre-registration is required. For additional information or to register, call (973) 443-8842. More information is available on the Web at http://view.fdu.edu/default.aspx?id=3712 .